Capital DailyCapital Daily
Markets · Investing · Business
Capital DailyCapital Daily
Finance

XLV vs. IBBQ: Is Broad Healthcare Exposure or Biotech Growth the Better ETF Buy?

IBBQ posted the stronger return over the past year, but has also experienced much higher historical volatility than XLV.

XLV vs. IBBQ: Is Broad Healthcare Exposure or Biotech Growth the Better ETF Buy?

Published August 1, 2026 · Category: Finance

Overview

The State Street Health Care Select Sector SPDR ETF (NYSEMKT:XLV) provides broad exposure to the S&P 500 healthcare sector, whereas the Invesco Nasdaq Biotechnology ETF (NASDAQ:IBBQ) offers a targeted focus on biotechnology and pharmaceutical companies listed on the Nasdaq.

Investors looking for healthcare exposure must often choose between the stability of a broad, diversified sector fund versus the higher upside -- and higher volatility -- of a narrower, growth-oriented fund. This comparison examines whether XLV's lower costs and track record outweigh the concentrated risk-reward profile of IBBQ.

Details

Beta measures price volatility relative to the S&P 500; beta is calculated from monthly returns over the available fund history (up to five years). The 1-year return represents total return over the trailing 12 months. Dividend yield is the trailing-12-month distribution yield.

Continue reading

Source

Originally published at www.fool.com.

Related Articles

CD
Capital Daily Newsroom

Capital Daily covers markets, crypto and commodities for Asia & the Middle East — tier-1 desk research, AI-driven analysis, institutional-grade data. Tip our newsroom: [email protected]

Email the newsroom →
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Data may be delayed up to 15 minutes. Past performance is not indicative of future results. Consult a licensed financial advisor before making investment decisions.